The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Congress 2022 | Leveraging inflammatory cytokine signaling for therapeutic benefit in MPNs
Stephen Oh
• 24 Nov 2022
Stephen Oh, MD, PhD, Washington University School of Medicine, Seattle, WA, gives a presentation on leveraging inflammatory cytokine signaling for therapeutic benefit in myeloproliferative neoplasms at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.
